ReviewJournal of clinical research in pediatric endocrinology2019
Pathogenesis of Thalassemia Major-associated Osteoporosis: A Review with Insights from Clinical Experience
Review in Journal of clinical research in pediatric endocrinology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06069089 (Assiut University, Pediatrician Department), which is not on this map. Cited by 43 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Assiut University, Pediatrician Department
Who cites it
43 citing papers in PubMed, 3 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- The Effects and Safety of Silymarin on β-thalassemia in Children and Adolescents: A Systematic Review based on Clinical Trial Studies.Reviews on recent clinical trials · 2024Pooled it
- Fracture prevalence in thalassemia: a systematic review and meta-analysis.Archives of osteoporosis · 2021Pooled it
- Vitamin D and bone health status in beta thalassemia patients-systematic review.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2021Pooled it
- The efficacy of alendronate for the treatment of thalassemia-associated osteoporosis: a randomized controlled trial.Frontiers in endocrinology · 2023Trial
- Physical activity, pain, and iron burden as independent correlates of quality of life in adults with beta-thalassemia major in the United Arab Emirates.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026Article
- Bisphosphonate therapy for thalassemia-related bone disorders in children and young adults: a systematic review.Annals of pediatric endocrinology & metabolism · 2026Article
- Article
- Use of romosozumab for osteoporosis in β-thalassemia major.JBMR plus · 2026Article
- Osteoporosis in children and adolescents with transfusion-dependent thalassemia and the diagnostic value of different indicators.BMC pediatrics · 2026Article
- Reproductive Endocrine Stability Despite Persistent Hypogonadism in Well-Chelated Adult Women with Transfusion-Dependent β-Thalassemia.Journal of clinical medicine · 2026Article
- Disproportionate Decline in Trabecular Bone Score Compared to Bone Mineral Density in Southeast Asian Patients with Thalassemia: A Matched Control Study.Calcified tissue international · 2026Article
- Vitamin D Deficiency as a Debatable Modulator of Outcomes in Transfusion-Dependent Thalassemia; An Overview of the Latest Findings: A Narrative Review.Health science reports · 2025Article
- CRISPR/Cas-edited iPSCs and mesenchymal stem cells: a concise review of their potential in thalassemia therapy.Frontiers in cell and developmental biology · 2025Review
- Trabecular bone score in the assessment of bone health in thalassemia major.Frontiers in endocrinology · 2025Article
- Risk factors of low bone mass in young patients with transfusion-dependent beta-thalassemia.Frontiers in endocrinology · 2025Article
- Article
- Relationship between hemoglobinopathies and male infertility: a scoping review.International journal of hematology · 2024Article
- Very low serum IGF-1 levels are associated with vertebral fractures in adult males with beta-thalassemia major.Journal of endocrinological investigation · 2024Article
- Endocrinopathies in beta thalassemia: a narrative review.Hormones (Athens, Greece) · 2024Review
- What are the treatment options for beta-thalassemia patients with osteoporosis? A Cochrane Review summary with commentary.Journal of musculoskeletal & neuronal interactions · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to increasing life expectancy in thalassemia major (TM), osteoporosis is emerging as a significant problem. Its aetiology is multifactorial, culminating in increased bone resorption and impaired remodelling. Hypogonadism and marrow expansion seem to play an important role, but iron overload, deferoxamine toxicity, a defective growth hormone-insulin-like growth factor-1 axis and multiple endocrinopathies may represent additional causes of bone damage. Many of these patients, though under appropriate treatment programs, do not achieve normal peak bone mass. The receptor activator of nuclear factor kappa-ß (RANK)/RANK ligand/osteoprotegerin and the Wnt/β-catenin systems work as major mediators of imbalanced bone turnover and bone loss. Additional genetic factors, such as collagen type 1 alpha 1 and vitamin D receptor gene polymorphisms, may exert some influence on the enhanced fracture risk observed in TM. To date, in spite of adequate hormone replacement, chelating therapy and acceptable haemoglobin levels, subjects with TM display impaired bone density and imbalanced bone turnover, thus the puzzle of the pathogenesis of TM-induced osteoporosis remains far from being solved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.